<DOC>
	<DOCNO>NCT02134210</DOCNO>
	<brief_summary>This two part study compare CHS-0214 Enbrel patient chronic plaque PsO yet receive biologic therapy indication ( insulin hormone ) .</brief_summary>
	<brief_title>Comparison CHS-0214 Enbrel ( Etanercept ) Patients With Chronic Plaque Psoriasis ( PsO )</brief_title>
	<detailed_description>Pt . 1 12-week randomize , double-blind , active-control , parallel-group , multi-center global study . The primary end point 75 % improvement baseline accord Psoriasis Area Severity Index ( PASI-75 ) . Comparing CHS-0214 Enbrel efficacy safety dosage 50mg subcutaneous ( Sc ) twice weekly . Pt . 2 40-week randomize , double-blind , active-control , parallel-group , multi-center global study CHS-0214 Enbrel dosage reduce 50mg Sc weekly maintenance .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Male female adult PsO diagnosis 6 month Active disease : PASI great equal 12 , Physician 's Static Global Assessment ( PSGA ) score great equal 3 ( base scale 05 ) , Body Surface Area ( BSA ) involve PsO great equal 10 % Dermatology Life Quality Index ( DQLI ) great equal 10 Previously receive phototherapy systemic nonbiologic therapy PsO Forms Psoriasis PsO Drug induce Psoriasis Positive QuantiFERONtuberculosis ( TB ) Gold Test Presence significant comorbid condition Chemistry hematology value outside protocol specify range Major systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>PsO</keyword>
</DOC>